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ABSTRACT 
Objective: To assess the risk of active TB in people with DM and the factors associated with this risk. 
 
Methods: Systematic review and meta-analysis. We searched the literature for studies that reported 
the effect of DM on TB controlled for the effect of age. Studies that had not established the 
diagnosis of DM prior to detecting active TB were excluded. Study quality was assessed by 
Newcastle-Ottawa scale and we conducted a meta-analysis using random-effects models. 
 
Results: 14 studies (8 cohort and 6 case-control studies) that involved 22,616,623 participants met 
the selection criteria and were included in the analysis. There was substantial variation between 
studies in the estimates of the effect of DM on TB. However, the pooled estimates from 7 
high-quality studies showed that diabetic people have a 1.5-fold increased risk of developing active 
TB versus those without DM (95%CI 1.28-1.76), with relatively small heterogeneity (I2 44%). The 
increased risk of TB was observed predominantly among DM populations with poor glycaemic 
control. 
 
Conclusion: There is evidence suggesting an increased risk of developing TB among people with DM, 
and that improving glycaemic control in DM patients would reduce the risk of developing TB. An 
integrated approach is needed to control the dual burden of DM and TB.  
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INTRODUCTION 
Tuberculosis (TB) continues to be a major global health challenge, with an estimated 10.4 million 
incident cases worldwide in 2016 (1). In addition to improving diagnosis and treatment of active TB, 
primary prevention through management of risk factors of TB is crucial for reducing the burden of 
TB because impairment of cell-mediated immunity that occurs in conditions such as HIV infection 
leads to a dramatic rise in the risk of developing active TB (2).  
 
 Diabetes mellitus (DM) can also impair host immunity (3) and the prevalence of DM is 
increasing all over the world, rising from 4.7% in 1980 to 8.5% in 2014 in the adult population (4). 
The rise is most remarkable in low- and middle-income countries (LMICs) even though a substantial 
proportion of people with DM living in LMICs remain undiagnosed. Availability of diagnostic tests 
and treatment required for management of DM in primary healthcare facilities is not universal in 
LMICs and this contributes to a high mortality attributable to DM that could be prevented.  
 
 Six countries (China, India, Brazil, Indonesia, Pakistan and The Russian Federation) among 
the ten projected to have the highest numbers of people living with DM by 2035 also have a high 
TB-burden (1). DM was observed to be a potential risk factor for TB long time ago (5), and the rising 
prevalence of DM in countries where TB is endemic has revived interest in exploring the relationship 
between DM and TB. A systematic review published in 2016 reported that DM was associated with 
an increased risk of latent TB infection (LTBI), with a risk ratio of 4.40 (95% CI; 0.50–38.55) in a 
cohort study, and a pooled odds ratio of 1.18 (95% CI; 1.06–1.30) from 13 cross-sectional studies (6). 
However, the latest WHO guideline on the management of LTBI does not recommend systematic 
testing for LTBI in people with DM based on lack of robust evidence that DM patients have a higher 
risk for LTBI (7). It is considered that the increased risk of active TB is mainly related to a higher risk 
of progression from LTBI among people with DM, and a meta-analysis published in 2008 suggests 
that DM triples the risk of developing active TB (8). However, in this meta-analysis, the pooled effect 
estimate of DM on TB (rate ratio 3.11, 95% Confidence Interval 2.27–4.26) was based on only three 
cohort studies, one of which did not control for potential confounders (9) and the other two cohort 
studies were conducted in renal transplant recipients who were under immunosuppressive therapy 
(10, 11). Furthermore, 9 of 13 studies included in the review did not establish the diagnosis of DM 
among participants prior to detecting active TB. Temporal sequence has been one of the major 
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concerns for investigating the effect of DM on TB risk because TB patients have higher rates of 
glucose intolerance than community controls (12, 13). Although it is unclear whether the stress of TB 
infection truly induces glucose intolerance, or whether prevalent DM was newly diagnosed through 
intensified medical services related to TB treatment, it would be vital to pay attention to this 
sequence to measure direct effect of DM on developing active TB. More studies of DM and TB 
infection have been published since 2008, but it remains unclear whether improving glycaemic 
control in DM patients could mitigate the risk of TB. Thus we conducted a systematic review and 
meta-analysis of studies investigating the association between DM and active TB.  
 
METHODS 
All studies published in English on the association between DM and active TB before April 13th, 2017 
were searched through PubMed, EMBASE, MEDLINE, and the Global Health database using a 
comprehensive search strategy (Supplement file 1). Bibliographies of identified articles were 
reviewed for additional relevant studies. Studies were screened and selected for full-text review if 
they met the following inclusion criteria: (1) reported a quantitative measure of association between 
DM and active TB; (2) diagnosis of DM was established prior to detecting TB; (3) TB diagnosis was 
based on standard diagnostic criteria; (4) diagnosis of DM was based on self-report, medical records, 
laboratory test or treatment. Systematic reviews and case reports were excluded from the analysis. 
We assessed the quality of study based on the Newcastle-Ottawa Scale (14) which assigns a 
maximum of 9 stars (4 for selection of study population, 2 for comparability, 3 for robustness of 
outcome or exposure). Studies that had a score more than 8 stars were deemed to be high quality. 
The selection of papers based on a priori criteria was done by one author (SH) and the screening 
process was repeated two months after the first screening to avoid exclusion of eligible articles by 
mistake. The quality assessment of papers included in the analysis was reached by consensus 
between both authors. 
 
 Data from each study were transcribed in a structured form and key study characteristics 
were summarized in a table. The reported relative risk (RR) of developing active TB among persons 
with DM compared to those without DM (rate ratios or odds ratios) was obtained from the model 
adjusted robustly for the potential confounding factors in each study. For studies that did not report 
the background TB incidence, data of the closest matching year of the study for the country were 
obtained from the WHO global tuberculosis database 
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(http://data.worldbank.org/indicator/SH.TBS.INCD). A meta-analysis was performed using Der 
Simonian-Laird random effects model and weighting method, accounting for the variation in the true 
effect of DM on TB in different populations. It was assumed that the odds ratio reported from 
case-control studies was a reasonable approximation of rate ratio since background TB incidence 
rates in the included studies were sufficiently low and none employed concurrent sampling (15). 
Thus, pooled estimates of relative risk were computed using either rate ratio or odds ratio. The 
observed relative risk of TB among persons with DM versus those without DM was stratified by the 
severity of DM, age, and sex within each study and presented in forest plots. In addition, other 
potential effect modifiers on the association between DM and TB were explored. Meta-regression 
was performed to explore between-study heterogeneity in effect estimates related to characteristics 
of the study population (region, background TB incidence, and median age of participants) and study 
characteristics (design, quality, median follow-up time, sample size, method of DM diagnosis, type of 
TB, and factors included in the regression models). Potential publication bias was assessed by visual 
interpretation of funnel plots of relative risks and their standard errors. All statistical analyses were 
done with Stata (version 14.2).  
 
 This systematic review was registered with the International Prospective Register of 
Systematic Reviews (PROSPERO), number CRD42017060873 
(http://www.crd.york.ac.uk/PROSPERO/). The results are presented in accordance to the Preferred 
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines (16).  
 
RESULTS 
Initially 4859 titles and abstracts were identified through comprehensive search of the databases. 
After the removal of duplicates, 3637 abstracts were screened, and 71 potential eligible articles 
were identified (Figure 1). After reading the full text, 57 studies were excluded for various reasons 
mentioned in Figure 1. Thus, 14 studies (8 cohort studies and 6 case-control studies), published 
between 1992 and 2017, which involved 22,616,623 participants, met the eligibility criteria for this 
analysis (9, 10, 17-28). 
 
 The key characteristics of the studies included in this analysis are shown in Table 1. Among 
the 8 cohort studies, 6 were conducted in general populations while one (South Korea) was done in 
civil servants (9), and one (India) was in renal transplant patients (10). Median follow-up time in the 
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cohort studies ranged from one to five years. Of the 6 case-control studies, 1 (Denmark) was 
nationwide (24) and 1 (Romania) was hospital-based (27). All studies had adjusted the rate ratio or 
odds ratio at least for age, and some studies had adjusted for a variety of potential confounders, 
such as sex, ethnicity, body mass index (BMI), or socio-economic status. Six of 8 cohort studies and 1 
of 6 case-control studies were of high quality (17, 18, 21, 23-25, 28). 
 
 There was substantial heterogeneity in the estimates of the effect of DM on the risk of 
active TB between the studies in both cohort and case-control studies; between-study variance 
accounted for 89.7% of the total variance among cohort studies and 90.1% of the total variance 
among case-control studies. However, all studies showed an increased risk of TB among persons 
with DM and the effect estimates reported by 12 of 14 studies were statistically significant. The 
pooled rate ratio estimated from the cohort studies showed that people with DM have a 1.95-fold 
(95%CI 1.38-2.76) increased risk of TB, and the pooled odds ratio from the case-control studies 
showed a 3.98-fold (95%CI 1.53-10.37) increased risk of TB. When low-quality studies were 
excluded, between-study heterogeneity decreased (I2=44.1%) and combining the estimates from 7 
high-quality studies showed that people with DM had a 1.5-fold higher risk of developing active TB 
than people without DM (95%CI 1.28-1.76).  
 
 The estimates of effect of DM on the risk of TB stratified by level of control of DM, age, and 
sex are presented in Figure 3. Six studies that compared the risk of TB by the severity of DM had 
used a variety of markers to define the level of control of DM such as plasma glucose level, 
haemoglobin A1c level, types of complications, and use of insulin. However, poorly controlled 
diabetes patients had a higher TB risk than patients with mild and well-controlled diabetes in all 
studies (Figure 3a). Age-stratified analysis in each study showed that the effect of DM on TB was 
stronger among younger than older people although this association was statistically significant in 
only 2 of 5 studies (Figure 3b). Sex was not found to be an effect modifier of the association between 
DM and TB (Figure 3c). Three large population-based studies had conducted stratified analysis by 
ethnicity, country of origin, indigenous status, and TB incidence in country of origin. None of these 
studies showed an effect of these factors modifying the association between DM and TB (26, 28, 31). 
 
 Figure 4 shows the potential source of heterogeneity in the magnitudes of the association 
between DM and TB observed in the studies, grouped by population characteristics and study 
characteristics. Overall, heterogeneity in relative risk was reduced when the studies were grouped 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
according to background TB incidence and study quality. There was a linear trend in the association 
between background TB incidence and the effect of DM on TB, with the relative risk rising from 1.46 
in low TB incidence countries (<15/100,000 person-years) to 3.96 in high TB incidence countries 
(>100/100,000 person-years) (p=0.036). However, this trend became statistically non-significant 
when controlled for the quality of studies (p=0.72). Effect of DM on TB differed by region, but 
regions except Asia and Europe included only one or two countries, which led to a large confidence 
interval. Studies in younger populations (median age <40) showed higher effect of DM on TB than 
studies in older populations (median age ≥40). Although this difference was not statistically 
significant, this is consistent with the results of age-stratified analyses. The strength of the 
association between DM and TB was lower in high-quality studies than that in low-quality studies 
(RR: 1.54 vs 3.83, p=0.001). This association remained statistically significant when adjusted for the 
effect of background TB incidence (RR 1.48 vs 3.39, p=0.04). Studies with shorter follow-up time, 
smaller sample size, and those that used self-report for diagnosis were associated with larger effect 
estimates of DM on TB risk. The funnel plot (Figure 5) shows an asymmetry of the reported effects of 
DM on TB. This is partly due to smaller studies showing larger effect estimates. 
 
DISCUSSION 
In comparison with the previous meta-analysis that was mainly based on one large cohort study that 
adjusted only for age, this study included six population-based large cohort studies that adjusted for 
the effect of several potential confounders. By excluding studies that did not establish DM diagnosis 
prior to developing TB, this study minimised potential reverse causality on the association between 
DM and TB, which made each study more comparable. This review also addressed the question of 
whether the risk of TB depends on the severity of DM. 
 
 Most studies demonstrated a dose-response association between the severity of DM and 
TB risk although a pooled estimate of this effect could not be calculated because each study used 
different markers for DM control level. Aside from DM markers presented in Figure 3, type 1 DM 
(T1DM) could be considered as a marker of severity since it often represents a more severe form of 
DM (29). Only two studies had investigated TB risk among people with T1DM (24, 28) and the 
relative risks observed in these studies were imprecise because the number of patients classified as 
T1DM was very small. A population-based historical cohort study in Taiwan that included 5195 
T1DM patients showed that TB risk was 4.36 (95%CI; 2.43–7.36) times greater among T1DM than 
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general population controls matched by age, sex, and other comorbidities (30). This association was 
much stronger than the risk of TB in persons with T2DM compared to non-DM people (adjusted RR; 
1.31 95%CI; 1.23–1.39) observed in a similar cohort study using the same database in Taiwan (31). 
Four of six studies included in this meta-analysis suggest that people with well-controlled DM were 
at lower risk than their non-DM counterparts (21, 23-25).  
 
 In a study that investigated the relationship between blood glucose levels and TB in HIV 
positive cohort of 12 western Pacific countries (32), there was a U-shaped relationship between 
glucose level and TB incidence, with the highest risk at both extremes. These findings may reflect the 
complicated role of BMI on the association between DM and TB. People with low glucose who are 
more likely to have a low BMI may be at higher risk of TB than people with well-controlled T2DM 
who are more likely to have a high BMI, in line with the evidence that higher BMI is an independent 
protective factor against TB (33, 34). In terms of age, there was a consistent trend of increasing TB 
risk in younger people with DM compared to older people with DM. It could be explained by higher 
proportion of younger diabetic people having T1DM (8). However, Kuo et al found a similar trend in 
a cohort study excluding T1DM, in which a stronger association of T2DM and TB were observed in 
people under the age of 40 years and a declining rate ratio in those over 40 years old. They 
suggested that elderly controls may have had an increased TB risk than younger ones, and this may 
dilute the apparent effect of DM. None of the other potential effect modifiers, such as sex, ethnicity, 
a country of origin, other comorbidities, and duration of DM were found to have a significant effect 
on the association between DM and TB. HIV status is another important factor strongly associated 
with TB, yet none of the studies included in this review investigated the effect of HIV status on the 
DM-TB association. In an HIV positive cohort (32), people whose glucose levels were >7 mmol/L had 
1.34-fold risk of TB (95%CI 1.01-1.79) compared to those with a glucose level <7 mmol/L after 
adjusting for potential confounders. A systematic review that investigated the effect of HIV on 
DM-TB association in Africa (35) concluded that there have been very few studies and the data were 
disparate. 
 
 The heterogeneity in the observed DM-TB association among studies was mainly explained 
by differences in three factors: study quality, region, and background TB incidence. Among these, 
study quality was the key explanatory factor for the between-study variability in the estimates of 
effect of DM on TB. Although TB incidence was likely to be lower in countries where high-quality 
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studies were conducted, the effect of DM on TB differed by study quality after adjusting for TB 
incidence. Large cohort study design with minimum bias, longer follow-up period, and adequate 
adjustment for confounders showed modest effect estimates of DM on TB. Although the strength of 
the DM-TB association varies between regions, ethnic difference is unlikely to be a main 
determinant for heterogeneity, considering the results that ethnicity and a country of origin did not 
modify the effect of DM on TB in any of the studies. Alternatively, difference in health systems or 
health utilisation patterns may explain the regional heterogeneity. In this analysis, there is no strong 
evidence that background TB incidence affects the strength of the DM-TB association. In addition to 
the quality of studies, high TB incidence setting may be indirectly related to larger disparities in TB 
susceptibility or exposure between DM and non-DM populations. Since there is evidence that 
poverty is associated not only with TB but also with a higher incidence of DM, poorer glycaemic 
control, and more diabetic complications (36-38), a lower-income setting is more likely to have 
poorly controlled DM patients. Based on these results, we developed an explanatory model 
illustrating the relationships between factors and the strength of the effect of DM on TB (Figure 6). 
In this model, lower-income setting is a common factor related to higher TB incidence, younger age 
distribution, lower study quality, and poorer DM control; consequently, it can lead to a stronger 
effect of DM on TB risk. 
 
 One explanation for the asymmetric distribution of the study results in the funnel plots 
would be that smaller studies with statistically insignificant effects were not published in 
English-language journals. However, it is essential to evaluate whether the asymmetry was due to 
true heterogeneity between the studies included in the meta-analysis. The magnitude of association 
between DM and TB was smaller in high quality studies but higher in low-quality studies (Figure 7a). 
Similarly, studies conducted in countries with higher annual per-capita health expenditure (a proxy 
measure to define level of control of DM) tend to show a modest effect of DM on TB (Figure 7b). 
There was a linear association between study quality and the strength of the association between 
DM and TB (p=0.026) (Figure 8a). There was a weak linear association between health expenditure 
per capita and the strength of the association between DM and TB (p=0.10) (Figure 8b), and this 
trend was statistically significant when the analysis excluded low-quality studies (p=0.04) (Figure 8c). 
These results support our hypothetical model explaining between-study heterogeneity, and it may 
also explain the asymmetric distribution of the results shown in the funnel plots. 
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 This study should be interpreted in light of several limitations. First, all studies were 
observational studies that are inherently at risk of biases. Differential misclassification of outcome 
(TB) might have occurred if doctors were more likely to screen DM patients for active TB. Selection 
bias would have occurred in studies that included only pulmonary TB (PTB) patients (9, 19, 22, 27). 
These studies might overestimate the effect of DM on TB risk since current findings consistently 
showed DM patients are more likely to develop PTB than extra-pulmonary TB compared to non-DM 
populations (25, 39-41). This may partly explain the result of meta-regression grouped by TB type: 
PTB group had a higher effect estimate (RR;3.63) than All-TB group (RR;2.08). Five studies relied 
exclusively on self-report for the diagnosis of DM (18-20, 22, 27), which could result in differential 
misclassification of exposure either by under-reporting or under-diagnosis of DM. A previous review 
reported that nearly half of adult DM patients globally were undiagnosed (42). In fact, 
meta-regression grouped by DM diagnosis method demonstrated a significantly higher effect 
estimate among studies based on self-report (RR;4.66, 95%CI;2.47-8.81) than those diagnosed based 
on laboratory data (RR;1.86 95%CI;0.90-3.86). This may imply that by using self-report, undiagnosed 
patients with mild asymptomatic DM were misclassified as non-DM while those with explicit 
symptoms and frequent medical treatment remained in the DM (self-report) group, which led to 
overestimating the effect of DM on TB. Second, the reported relative risks may have been 
confounded by unmeasured social and health risk factors such as BCG immunisation, contact with TB 
patients, or HIV status. Third, as this systematic review is restricted to studies reported in English, 
the risk of language bias could not be ruled out (43, 44). The asymmetric distribution seen in the 
funnel plot may suggest that studies showing statistically significant association between DM and TB 
were more likely to be published in English-language journals. Fourth, only including studies in 
middle and high-income countries may limit the generalizability of our results to low-income 
countries. Despite the use of comprehensive terms in several databases and the inclusion criteria 
allowing self-report as diagnosis of DM, we were unable to include any studies from Africa and 
South-east Asia where the large burden of TB lies. Studies from those countries were excluded 
because they did not establish DM diagnosis prior to detecting TB or did not adjust for age. 
However, most of the excluded studies conducted in low-income countries showed substantial 
effect of DM on TB risk, and our analyses (Figure 7, 8) in addition to our model (Figure 6) implied 
that lower-income setting is associated with higher effect of DM on TB risk. Fifth, the results from 
meta-regression should be carefully interpreted because they are in danger of ecological fallacy as 
summary data may not always reflect on individual level data. In addition, these analyses were 
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post-hoc and consequently at risk of over-interpretation. Despite these limitations, however, this 
meta-analysis showed a robust evidence of the association between DM and TB.  
 
CONCLUSION 
Based on this meta-analysis, if we assume there is a causal relationship between DM and TB and the 
observed RR of 1.5 is generalizable globally, as the global prevalence of DM is estimated as 8.5% (4), 
DM would account for 33% of active TB cases among people with DM, and 4.1% of all TB cases can 
be averted by prevention of DM globally. Our review also suggests that glycaemic control for DM 
patients would have a similar impact on prevention of TB, since people with well-controlled DM 
have similar risk of TB as non-DM populations. Indeed, Lee et al estimated that 7.5% (95%CI; 
4.1%–11.5%) of all TB cases in Taiwan population would have been prevented if all DM patients had 
achieved good glycaemic control (23). Another option to prevent active TB would be testing for LTBI 
among DM patients and offering chemo-prevention with isoniazid for those with positive results. 
Although DM is associated with increased risk of active TB, it is still unclear whether DM increases 
primary TB infection or reactivation of LTBI, and previous studies did not provide clear evidence on 
the effectiveness of preventive therapy with isoniazid for DM people having LTBI (45, 46). 
 
 Evidence on the link between DM and TB has grown, yet there remain many uncertainties. 
To inform policy-makers on optimum management strategies for this dual epidemic, our findings 
suggest that research should continue to explore: (1) effect of DM on TB risk in the general 
population of LMICs with robust study design, (2) interaction of HIV on DM-TB association in 
countries with HIV epidemic, (3) interaction of nutritional status on DM-TB association, (4) effect of 
glycaemic control for DM among TB patients on TB treatment outcomes, (5) efficacy, effectiveness, 
and cost-effectiveness of LTBI screening for DM patients, followed by chemoprophylaxis for those 
with positive results. 
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Table 1 Summary characteristics of study 
Study Country, Population Period Exposure (Diabetes Mellitus) Outcome (Tuberculosis) RRⅰ Study Quality
xiii
 
Cohort Study 
Kim et al, 
1995 
South Korea, Civil servants 
N=839280  
1988- 
1990 
RPGⅱ≥119 mg/dl at screening, followed by 
FPGⅲ≥150 mg/dl and PPPGⅳ≥180 mg/dl 
PTBⅴ determined by chest 
X-ray and/or sputum 
examination 
3.58ⅵ 
(3.08-4.16) 
S★★★ C★ 
O★★ Overall 6 
John et al, 
2001 
India, Vellore, renal transplant 
recipients, N=1414 
1986- 
1999 
FPG>120 mg/dl or PPPG>200 mg/dl ; two 
elevated levels of either measurement 
Clinical diagnosis and/or X-ray, 
AFBⅶ, culture of affected tissue 
2.24  
(1.38-3.65) 
S★★ C★★ 
O★★ Overall 6 
Leung et 
al, 2008 
Hong-Kong, Community-based 
health program, N=42,116  
2000- 
2005 
FPG≥7.0 mmol /litre and/or blood/plasma 
glucose determinants  
microbiological and/or clinical 1.77  
(1.41-2.24) 
S★★★★ C★★ 
O★★★ Overall 9 
Baker et 
al, 2012 
Taiwan, NHISⅻ 
N=17,715 
2001- 
2004 
self-report, ICDⅷ code or DM medication  ICD code on NHIⅸ database 2.09  
(1.10-3.95) 
S★★★★ C★★ 
O★★ Overall 8 
Dobler et 
al, 2012 
Australia, General population  
N=19855283  
2001- 
2006 
Self-report confirmed by health professional Notification database of active 
TB case 
1.48  
(1.04-2.10) 
S★★★★ C★★ 
O★★★ Overall 9 
Chen et al, 
2013  
China, All residents in two rural 
counties, N=177529 
2009- 
2011 
Self-report All type of TB based on national 
criterion  
2.43ⅹ 
(0.84-7.00) 
S★★★★ C★★ 
O★★ Overall 8 
Pealing et 
al, 2015 
United Kingdom, General 
population, N=1664078  
1990– 
2013 
National Health Service (NHS) Read codes. A list of NHS Read codes for all 
forms of tuberculosis 
1.30  
(1.01-1.67) 
S★★★★ C★★ 
O★★★ Overall 9 
Lee et al, 
2016 
Taiwan, Community-based health 
screening participants, N= 123546 
2005- 
2012 
Prescription of hypoglycemic drug or FPG ≥ 
126 mg/dl 
ICD9 + prescription of anti-TB 
treatment for ≥90d 
1.70  
(1.27-2.27) 
S★★★★ C★★ 
O★★★ Overall 9 
Case-control study 
Mori et al, 
1992 
United States, Native Americans in 
South Dakoda, N=92  
1983- 
1989 
FPG>7.8mmol/L or any glucose level >11.1 
mmol/L or received diabetic treatment 
Indian Health Service hospital 
and clinics charts 
5.2  
(1.22-22.1) 
S★★★★ C★ 
E★★ Overall 7 
Coker et Russia, Residents in Samara  2003 Self-report culture confirmed PTB 7.83  S★★★ C★★ 
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al, 2006 N=668 (2.37- 25.89) E★ Overall 6 
Leegaard 
et al, 2011 
Denmark, People in northern 
Denmark, N= 17224 
1980- 
2008 
DNRPⅺ validated algorithm, Prescription 
Database and Danish NHISⅻ Registry 
First time TB diagnosis in 
hospital records based on ICD 
1.18  
(0.96-1.45) 
S★★★★ C★★ 
E★★ Overall 8 
Jurcev-S 
et al, 2013 
Croatia, People in seven randomly 
selected counties, N=600 
2006- 
2008 
Self-report  Culture positive PTB 2.38  
(1.05-5.38) 
S★★★ C★★ 
E★ Overall 6 
Davis et 
al, 2017 
Kazakhstan, People in four 
disperse regions, N=1600 
2012- 
2014 
Self-report microbiological and/or clinical 
 
13.96 
(6.37-30.56) 
S★★★ C★★ 
E★ Overall 6 
Ndishimye 
et al, 2017 
Romania, Patients in a clinical 
hospital, N=300 
2014- 
2015 
Self-report PTB confirmed by WHO and 
national guideline 
3.32 
(1.36-8.08) 
S★★ C★★ 
E★ Overall 5 
ⅰRelative Risk (Adjusted rate ratio in cohort studies and adjusted odds ratio in case-control studies on developing active TB comparing DM vs no DM), ⅱRPG; Random plasma glucose, 
ⅲFPG; Fasting plasma glucose, ⅳPPPG; Postprandial plasma glucose, ⅴPTB; Pulmonary tuberculosis, ⅵOriginal article presented only crude RR; therefore, age-adjusted RR was 
calculated using Mantel-Haenszel weighting method, ⅶAFB; Acid-fast bacilli stain, ⅷICD; International classification of diseases, ⅸNHI; National health insurance, ⅹA pooled estimate 
was calculated using Mantel-Haenszel weighting method from the original data (Xiangtan: 1.31 (0.17-9.97), Danyang: 3.05 (0.88-10.55)), ⅺDNRP; Danish national registry of patients, 
ⅻNHIS; National health insurance service, 
xiii 
Study quality- S; Selection, C; Comparability, O; Outcome, E; Exposure, Overall score 8-9; high -7; low 
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